Skip to main content
Clinical Trials/NCT02701374
NCT02701374
Completed
Phase 2

TRK-700 An Early Phase II Study in Patients With Post-Herpetic Neuralgia -Double Blind Comparison With Placebo-

Toray Industries, Inc1 site in 1 country184 target enrollmentMarch 2016

Overview

Phase
Phase 2
Intervention
TRK-700
Conditions
Post-Herpetic Neuralgia
Sponsor
Toray Industries, Inc
Enrollment
184
Locations
1
Primary Endpoint
Change in average Numerical Rating Scale (NRS)
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

In Post-Herpetic Neuralgia(PHN) patients:

  • To conduct an explorative investigation of the efficacy and safety of repeated oral doses of TRK-700 via a randomized double blind comparative study
  • To measure the plasma concentration of TRK-700 and its metabolites
Registry
clinicaltrials.gov
Start Date
March 2016
End Date
July 2017
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients with pain persisting for at least 3 months after the onset of herpes zoster
  • Patients whose average pain score on the Numerical Rating Scale (NRS) over the past 24 hours at preliminary enrollment is at least 4

Exclusion Criteria

  • Patients with another skin disease that may affect the evaluation of the pain at the site of PHN
  • Patients with pain other than PHN that may affect the evaluation of pain
  • Patients with pain that is suspected to be mainly psychogenic
  • Patients who have received neurolytic or neurosurgical therapy for PHN

Arms & Interventions

1:TRK-700

high dose

Intervention: TRK-700

2:TRK-700

low dose

Intervention: TRK-700

3:Placebo

Placebo

Intervention: Placebo

Outcomes

Primary Outcomes

Change in average Numerical Rating Scale (NRS)

Time Frame: baseline to week 8

Change in average NRS collected by Pain Diary from baseline to week 8 in subjects receiving TRK-700 versus Placebo

Study Sites (1)

Loading locations...

Similar Trials